Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.525
Journals
Pharmaceutics
Special Issues
Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions, 2nd Edition
share announcement

Special Issue "Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions, 2nd Edition"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".

Deadline for manuscript submissions: 28 February 2024 | Viewed by 685

Special Issue Editors

Dr. Kyeong-Ryoon Lee

E-Mail Website
Guest Editor
Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Republic of Korea
Interests: pharmacokinetics; physiologically based pharmacokinetic (PBPK) modeling and simulation; pharmacokinetic–pharmacodynamic (PK-PD) modeling and simulation; drug–drug interaction (DDI); in vitro–in vivo extrapolation (IVIVE)
Special Issues, Collections and Topics in MDPI journals
Dr. Yoon-Jee Chae

E-Mail Website
Guest Editor
College of Pharmacy, Woosuk University, Wanju-gun 55338, Republic of Korea
Interests: pharmacokinetics; drug interactions; transrpoters; CYP450 induction; pharmacokinetic alteractions in disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleague,

Pharmacokinetics and pharmacodynamics are important evaluation steps for understanding the behavior of drugs and their efficacy after administration in drug development. Drug interaction studies are also essential in drug development, and aid in the preparation of drug development strategies in clinical studies. In conventional studies, pharmacokinetics, pharmacodynamics and drug interactions have been considered as purely analytical tools, but these days they are applied to predict drug properties in inter-species studies, including in humans, along with model-based approaches. These research studies have increased in number, leading to new technologies or platforms being introduced; therefore, it is expected that various research outputs will be reported.

We invite research scientists who study pharmacokinetics, pharmacodynamics and drug interactions to submit original research articles, review articles or commentaries. This Special Issue will provide researchers with information and an up-to-date resource.

Dr. Kyeong-Ryoon Lee
Dr. Yoon-Jee Chae
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacokinetics
  • pharmacodynamics
  • PK/PD modeling
  • drug–drug interactions
  • PBPK model
  • drug delivery
  • drug development

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

get_app
Communication
Influence of Intramuscular Injection Sites on Pharmacokinetics of Amoxicillin in Olive Flounder (Paralichthys olivaceus) and Its Implication for Antibacterial Efficacy
by
Ji-Hoon Lee
,
Ga-Won Kim
,
Hyun-Woo Kang
,
Joo-Won Hong
,
Hyo-Eun Lee
,
Mun-Gyeong Kwon
and
Jung-Soo Seo
Pharmaceutics 2023, 15(4), 1153; https://doi.org/10.3390/pharmaceutics15041153 - 05 Apr 2023
Viewed by 515
Abstract
This study aimed to investigate the effects of different injection sites, including dorsal, cheek, and pectoral fin muscles, on the pharmacological properties of amoxicillin (AMOX) in olive flounder (Paralichthys olivaceus) after a single intramuscular (IM) injection of 40 mg/kg. The AMOX [...] Read more.
This study aimed to investigate the effects of different injection sites, including dorsal, cheek, and pectoral fin muscles, on the pharmacological properties of amoxicillin (AMOX) in olive flounder (Paralichthys olivaceus) after a single intramuscular (IM) injection of 40 mg/kg. The AMOX concentration was measured using high-performance liquid chromatography-tandem mass spectrometry, followed by a non-compartmental model analysis. The peak serum concentrations (Cmax) achieved 3 h after dorsal, cheek, and pectoral fin IM injections were 202.79, 203.96, and 229.59 μg/mL, respectively. The area under the concentration-time curve (AUC) was 1697.23, 2006.71, and 1846.61 µg/mL·h, respectively. The terminal half-life (t1/2λZ) was prolonged for cheek and pectoral fin IM injections (10.12 and 10.33 h, respectively) compared to dorsal IM injection (8.89 h). In the pharmacokinetic-pharmacodynamic analysis, a higher T > minimum inhibitory concentration (MIC) and AUC/MIC values were observed after AMOX was injected into the cheek and pectoral fin muscles compared to the dorsal muscle. Muscle residue depletion was below the maximum residue level from day 7 after IM injection at all three sites. These findings suggest that the cheek and pectoral fin sites provide advantages regarding systemic drug exposure and prolonged action compared with the dorsal site. Full article
(This article belongs to the Special Issue Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions, 2nd Edition)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop